00853 微創醫療
按盘价 
6.620 -0.080 (-1.194%) 盈利能力分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 资产回报率 (%) | -5.658% | -12.051% | -10.425% | -8.073% | -9.405% |
| 股东资金回报率 (%) | -31.447% | -50.467% | -33.248% | -21.116% | -23.224% |
| 资本运用回报率 (%) | -8.721% | -18.596% | -13.101% | -7.212% | -9.809% |
边际利润分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 毛利率 (%) | 55.680% | 55.968% | 59.676% | 63.158% | 67.213% |
| 未计利息、税项、折旧及摊销前利润率 (%) | 1.205% | -39.913% | -40.238% | -25.497% | -16.033% |
| 税前边际利润率 (%) | -21.801% | -65.899% | -69.160% | -43.322% | -32.824% |
| 纯利率 (%) | -20.759% | -50.238% | -51.915% | -35.509% | -29.481% |
变现能力分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 流动比率 (X) | 1.473 X | 1.474 X | 2.929 X | 4.365 X | 2.849 X |
| 速动比率 (X) | 1.152 X | 1.170 X | 2.397 X | 3.835 X | 2.387 X |
财务杠杆分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 总负债 / 总资产比率 (%) | 68.491% | 64.322% | 55.117% | 49.378% | 43.788% |
| 总债项 / 总资产比率 (%) | 46.381% | 43.199% | 36.753% | 28.391% | 12.001% |
| 净债项 / 总资产比率 (%) | 26.758% | 17.272% | 6.633% | -11.659% | -28.584% |
| 总债项 / 股东资金比率 (%) | 279.252% | 224.163% | 129.331% | 83.427% | 26.269% |
| 长期债项 / 股东资金比率 (%) | 195.513% | 106.480% | 108.421% | 73.684% | 24.234% |
| 净债项 / 股东资金比率 (%) | 161.103% | 89.625% | 23.342% | -34.259% | -62.570% |
| 净现金 / (债项) ($) | (9.72亿) | (6.79亿) | (2.65亿) | 5.11亿 | 7.06亿 |
| 每股净现金 / (债项) ($) | (0.526) | (0.370) | (0.145) | 0.280 | 0.390 |
| 总债项 / 资本运用比率 (%) | 68.660% | 66.138% | 44.057% | 32.440% | 15.197% |
| 利息盈利率 (X) | N/A | N/A | N/A | N/A | N/A |
营运效率分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 存货周转率日数 (日) | 317.161日 | 334.502日 | 345.752日 | 337.253日 | 371.099日 |
| 应收贸易帐周转率日数 (日) | 80.020日 | 68.591日 | 77.414日 | 81.240日 | 104.503日 |
| 应付贸易帐周转率日数 (日) | 63.797日 | 63.176日 | 59.539日 | 44.871日 | 42.341日 |
| 备注： | 实时报价更新时间为16/05/2025 17:59 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) (千) | USD -214,043 |
| 增长率 | -55.186% |
| 每股盈利/(亏损) | USD -0.117 |
| 每股账面资产净值 ($) | USD 0.327 |